|Bid||330.45 x 1300|
|Ask||330.04 x 1100|
|Day's Range||308.24 - 331.00|
|52 Week Range||54.10 - 331.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||195.09|
BioNTech (NASDAQ: BNTX) has begun to spend some of the cash generated by its COVID-19 vaccine. The German drugmaker recently announced an agreement with Gilead Sciences (NASDAQ: GILD) to acquire a research program and a manufacturing site. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss what investors should like about BioNTech's deal with Gilead.
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
The CDC's internal documents shed more light on the dangers of the Delta variant.